SAN DIEGO--(BUSINESS WIRE)--Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced unaudited financial results for the three months ended March 31, 2008.
